Neurotrophic keratitis is well explored in the cover story of this issue of Healio | OSN.
The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal epitheliopathy associated with reduced or absent corneal sensation. I would like to share a few personal thoughts for the practicing clinician after managing these difficult-to-treat patients for 5 decades.
The corneal epithelium usually heals well and rapidly, and a PED occurs in only 200,000 or so patients each year.